Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02780011
Title Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors The Methodist Hospital System

skin angiosarcoma

embryonal testis carcinoma


Advanced Solid Tumor

nasopharynx carcinoma


Alisertib + Brentuximab vedotin

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Houston Methodist Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from for the field